NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology. This nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial Antigen Presenting Cells (aAPC) that present antigens to T cells eliciting a highly targeted therapy driven by the patient’s immune system. These aAPC can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.
Location: United States, Maryland, Gaithersburg
Employees: 51-200
Total raised: $23M
Founded date: 2011
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.01.2018 | - | $23M | - |
Mentions in press and media 10
| Date | Title | Description |
| 12.05.2026 | Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer | European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS Dr. Myint, a hematology lead... |
| 19.02.2021 | Shorties Roundup: More workers in DC now qualify to get the coronavirus vaccine | More workers in D.C. can now get the coronavirus vaccine. As of Thursday, Feb. 18, the District government has expanded vaccine eligibility to include grocery store, health and human services, social services, food packaging and manufacturi... |
| 29.04.2019 | MMRF Venture Philanthropy Fund Invests in NexImmune | GAITHERSBURG, Md. and NORWALK, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- NexImmune and the Multiple Myeloma Research Foundation (MMRF) have entered into a partnership to advance a promising new therapy into clinical trials for multiple myel... |
| 29.04.2019 | MMRF Venture Philanthropy Fund Invests in NexImmune | GAITHERSBURG, Md. and NORWALK, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- NexImmune and the Multiple Myeloma Research Foundation (MMRF) have entered into a partnership to advance a promising new therapy into clinical trials for multiple myel... |
| 08.08.2018 | SQZ Biotech raises $72M in Series C funding round | The company will initially apply its lead program, in antigen-presenting cells, in a number of human papillomavirus-related tumor indications, while future applications will address solid tumors across cancer types. That program is in precl... |
| 02.01.2018 | NexImmune Raises $23 Million | GAITHERSBURG, Md., Jan. 02, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor... |
| 21.07.2014 | NexImmune Secures $3M | GAITHERSBURG, MD, Early stage biopharmaceutical company, today announced it has secured $3 million in financing led by New Enterprise Associates. >> Click here for more funding data on NexImmune >> To export NexImmune fundin... |
| 09.02.2012 | Artificial immune cell treatment for melanoma aims for human trials in 2013 | “The big caveat is that all of them are based either on raw administration of antigens that you hope the immune system will take up, or on taking cells out of the body, loading them with an antigen and put them back in body,” said CEO Kenne... |
| - | SQZ Biotech raises $72M in Series C funding round | A company developing cell therapies for cancers and autoimmune diseases has closed a financing round three times the size of the last one. Watertown, Massachusetts-based SQZ Biotechnologies said Wednesday that it had raised $72 million in a... |
| - | Artificial immune cell treatment for melanoma aims for human trials in 2013 | A new treatment for cancer that uses artificial immune cells to trigger the body to kill cancerous cells will raise a series A round this spring and look to an investigational new drug (IND) application next year. NexImmune is an early stag... |